medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2013, Número 07-08

<< Anterior Siguiente >>

Medicina & Laboratorio 2013; 19 (07-08)


Deficiencia de hormona del crecimiento en el adulto

Builes MCE, Campuzano MG

Idioma: Español
Referencias bibliográficas: 97
Paginas: 337-352
Archivo PDF: 465.11 Kb.


RESUMEN

La hormona del crecimiento tiene funciones más allá de la que su nombre implica. En el adulto es una hormona importante en el metabolismo de lípidos y carbohidratos, cumple funciones vitales en estados de ayuno y juega un papel preponderante en el equilibrio energético del organismo. La deficiencia de hormona del crecimiento es una entidad bien reconocida en la edad pediátrica, con consecuencias bien establecidas y fácilmente identificables; en contraste, su deficiencia en la edad adulta es más difícil de establecer y puede obedecer a causas congénitas o adquiridas durante la infancia o a causas adquiridas en la edad adulta. En años recientes, así como ha ocurrido en diversos campos de la farmacología, se ha podido aislar y sintetizar una forma recombinante de la hormona del crecimiento humana, lo cual ha abierto la posibilidad de tratamiento para las personas con deficiencia de dicha hormona. Sin embargo, hay muchos interrogantes con respecto a la deficiencia de hormona del crecimiento en el adulto, entre ellos, el diagnóstico adecuado y los verdaderos beneficios y la seguridad del tratamiento con hormona del crecimiento humana recombinante. En este módulo se realiza un estado del arte acerca de la deficiencia de hormona del crecimiento en los adultos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ho KK, O’Sullivan AJ, Hoffman DM. Metabolic actions of growth hormone in man. Endocr J 1996; 43 Suppl: S57-63.

  2. Frohman LA, Burek L, Stachura MA. Characterization of growth hormone of different molecular weights in rat, dog and human pituitaries. Endocrinology 1972; 91: 262-269.

  3. Van Cauter E, Plat L, Copinschi G. Interrelations between sleep and the somatotropic axis. Sleep 1998; 21: 553-566.

  4. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998; 19: 717-797.

  5. Lanfranco F, Gianotti L, Giordano R, Pellegrino M, Maccario M, Arvat E. Ageing, growth hormone and physical performance. J Endocrinol Invest 2003; 26: 861-872.

  6. Ho KY, Veldhuis JD, Johnson ML, Furlanetto R, Evans WS, Alberti KG, et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest 1988; 81: 968-975.

  7. Vigas M, Malatinsky J, Nemeth S, Jurcovicova J. Al- pha-adrenergic control of growth hormone release during surgical stress in man. Metabolism 1977; 26: 399-402.

  8. Sachar EJ, Frantz AG, Altman N, Sassin J. Growth hormone and prolactin in unipolar and bipolar depressed patients: responses to hypoglycemia and L-dopa. Am J Psychiatry 1973; 130: 1362-1367.

  9. Dayal Y, Lin HD, Tallberg K, Reichlin S, DeLellis RA, Wolfe HJ. Immunocytochemical demonstration of growth hormone-releasing factor in gastrointestinal and pancreatic endocrine tumors. Am J Clin Pathol 1986; 85: 13-20.

  10. Frohman LA, Szabo M, Berelowitz M, Stachura ME. Partial purification and characterization of a peptide with growth hormone-releasing activity from extrapituitary tumors in patients with acromegaly. J Clin Invest 1980; 65: 43-54.

  11. Guillemin R, Brazeau P, Bohlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 1982; 218: 585-587.

  12. Mayo KE, Vale W, Rivier J, Rosenfeld MG, Evans RM. Expression-cloning and sequence of a cDNA encoding human growth hormone-releasing factor. Nature 1983; 306: 86-88.

  13. Muller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev 1999; 79: 511-607.

  14. Smith RG, Feighner S, Prendergast K, Guan X, Howard A. A new orphan receptor involved in pulsatile growth hormone release. Trends Endocrinol Metab 1999; 10: 128-135.

  15. Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab 2001; 86: 1169-1174.

  16. Ross RJ, Tsagarakis S, Grossman A, Nhagafoong L, Touzel RJ, Rees LH, et al. GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH. Clin Endocrinol (Oxf) 1987; 27: 727-733.

  17. Zheng H, Bailey A, Jiang MH, Honda K, Chen HY, Trumbauer ME, et al. Somatostatin receptor subtype 2 knockout mice are refractory to growth hormone- negative feedback on arcuate neurons. Mol Endocrinol 1997; 11: 1709-1717.

  18. Muller EE. Cholinergic function and neural control of GH secretion. A critical re-appraisal. Eur J Endocrinol 1997; 137: 338-342.

  19. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009; 30: 152-177.

  20. Wurzburger MI, Prelevic GM, Sonksen PH, Balint-Peric LA, Wheeler M. The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin- dependent diabetes. J Clin Endocrinol Metab 1993; 77: 267-272.

  21. Clemmons DR, Underwood LE. Nutritional regulation of IGF-I and IGF binding proteins. Annu Rev Nutr 1991; 11: 393-412.

  22. Giannoulis MG, Jackson N, Shojaee-Moradie F, Nair KS, Sonksen PH, Martin FC, et al. The effects of growth hormone and/or testosterone on whole body protein kinetics and skeletal muscle gene expression in healthy elderly men: a randomized controlled trial. J Clin Endocrinol Metab 2008; 93: 3066-3074.

  23. Attallah H, Friedlander AL, Nino-Murcia M, Hoffman AR. Effects of growth hormone and pioglitazone in viscerally obese adults with impaired glucose tolerance: a factorial clinical trial. PLoS Clin Trials 2007; 2: e21.

  24. Gravholt CH, Schmitz O, Simonsen L, Bulow J, Christiansen JS, Moller N. Effects of a physiological GH pulse on interstitial glycerol in abdominal and femoral adipose tissue. Am J Physiol 1999; 277: E848-854.

  25. Beauville M, Harant I, Crampes F, Riviere D, Tauber MT, Tauber JP, et al. Effect of long-term rhGH administration in GH-deficient adults on fat cell epinephrine response. Am J Physiol 1992; 263: E467-472.

  26. Richelsen B, Pedersen SB, Kristensen K, Borglum JD, Norrelund H, Christiansen JS, et al. Regulation of lipoprotein lipase and hormone-sensitive lipase activity and gene expression in adipose and muscle tissue by growth hormone treatment during weight loss in obese patients. Metabolism 2000; 49: 906-911.

  27. Paulsen SK, Pedersen SB, Jorgensen JO, Fisker S, Christiansen JS, Flyvbjerg A, et al. Growth hormone (GH) substitution in GH-deficient patients inhibits 11beta-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression in adipose tissue. J Clin Endocrinol Metab 2006; 91: 1093-1098.

  28. Rudling M, Norstedt G, Olivecrona H, Reihner E, Gustafsson JA, Angelin B. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci U S A 1992; 89: 6983-6987.

  29. Bengtsson BA. Untreated growth hormone deficiency explains premature mortality in patients with hypopituitarism. Growth Horm IGF Res 1998; 8 Suppl A: 77-80.

  30. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001; 357: 425-431.

  31. Moller N, Jorgensen JO, Alberti KG, Flyvbjerg A, Schmitz O. Short-term effects of growth hormone on fuel oxidation and regional substrate metabolism in normal man. J Clin Endocrinol Metab 1990; 70: 1179- 1186.

  32. Kaplan W, Sunehag AL, Dao H, Haymond MW. Shortterm effects of recombinant human growth hormone mapnudz faeneodi-nMg aoyna g Glu.coneogenesis in humans. Metabolism 2008; 57: 725-732.

  33. Schwarz JM, Mulligan K, Lee J, Lo JC, Wen M, Noor MA, et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2002; 87: 942.

  34. Copeland KC, Nair KS. Acute growth hormone effects on amino acid and lipid metabolism. J Clin Endocrinol Metab 1994; 78: 1040-1047.

  35. Nielsen S, Jorgensen JO, Hartmund T, Norrelund H, Nair KS, Christiansen JS, et al. Effects of lowering circulating free fatty acid levels on protein metabolism in adult growth hormone deficient patients. Growth Horm IGF Res 2002; 12: 425-433.

  36. Garibotto G. Muscle amino acid metabolism and the control of muscle protein turnover in patients with chronic renal failure. Nutrition 1999; 15: 145-155.

  37. Horber FF, Haymond MW. Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest 1990; 86: 265-272.

  38. Cahill GF, Jr. Starvation in man. N Engl J Med 1970; 282: 668-675.

  39. Wheldon A, Savine RL, Sonksen PH, Holt RI. Exercising in the cold inhibits growth hormone secretion by reducing the rise in core body temperature. Growth Horm IGF Res 2006; 16: 125-131.

  40. Kanaley JA, Dall R, Moller N, Nielsen SC, Christiansen JS, Jensen MD, et al. Acute exposure to GH during exercise stimulates the turnover of free fatty acids in GH-deficient men. J Appl Physiol 2004; 96: 747-753.

  41. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341: 785-792.

  42. McNurlan MA, Garlick PJ, Steigbigel RT, DeCristofaro KA, Frost RA, Lang CH, et al. Responsiveness of muscle protein synthesis to growth hormone administration in HIV-infected individuals declines with severity of disease. J Clin Invest 1997; 100: 2125-2132.

  43. Stochholm K, Gravholt CH, Laursen T, Jorgensen JO, Laurberg P, Andersen M, et al. Incidence of GH deficiency - a nationwide study. Eur J Endocrinol 2006; 155: 61-71.

  44. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1587-1609.

  45. Molitch ME. Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin North Am 2008; 37: 151-171, xi.

  46. Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML. Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q J Med 1989; 70: 145-160.

  47. Schneider HJ, Kreitschmann-Andermahr I, Ghigo E, Stalla GK, Agha A. Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA 2007; 298: 1429-1438.

  48. van Coevorden A, Mockel J, Laurent E, Kerkhofs M, L’Hermite-Baleriaux M, Decoster C, et al. Neuroendocrine rhythms and sleep in aging men. Am J Physiol 1991; 260: E651-661.

  49. Lissett CA, Shalet SM. The insulin-like growth factor-I generation test: peripheral responsiveness to growth hormone is not decreased with ageing. Clin Endocrinol (Oxf) 2003; 58: 238-245.

  50. Abs R, Feldt-Rasmussen U, Mattsson AF, Monson JP, Bengtsson BA, Goth MI, et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. Eur J Endocrinol 2006; 155: 79-90.

  51. Christ ER, Carroll PV, Russell-Jones DL, Sonksen PH. The consequences of growth hormone deficiency in adulthood, and the effects of growth hormone replacement. Schweiz Med Wochenschr 1997; 127: 1440-1449.

  52. Mazziotti G, Bianchi A, Bonadonna S, Nuzzo M, Cimino V, Fusco A, et al. Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J Bone Miner Res 2006; 21: 520-528.

  53. Beshyah SA, Gelding SV, Andres C, Johnston DG, Gray IP. Beta-cell function in hypopituitary adults before and during growth hormone treatment. Clin Sci (Lond) 1995; 89: 321-328.

  54. Yuen KC, Frystyk J, White DK, Twickler TB, Koppeschaar HP, Harris PE, et al. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin Endocrinol (Oxf) 2005; 63: 428-436.

  55. Gilchrist FJ, Murray RD, Shalet SM. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults. Clin Endocrinol (Oxf) 2002; 57: 363-370.

  56. Sathiavageeswaran M, Burman P, Lawrence D, Harris AG, Falleti MG, Maruff P, et al. Effects of GH on cognitive function in elderly patients with adult-onset GH deficiency: a placebo-controlled 12-month study. Eur J Endocrinol 2007; 156: 439-447.

  57. Thum T, Hoeber S, Froese S, Klink I, Stichtenoth DO, Galuppo P, et al. Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone- mediated increase of insulin-like growth-factor-1. Circ Res 2007; 100: 434-443.

  58. Li G, Del Rincon JP, Jahn LA, Wu Y, Gaylinn B, Thorner MO, et al. Growth hormone exerts acute vascular effects independent of systemic or muscle insulin-like growth factor I. J Clin Endocrinol Metab 2008; 93: 1379-1385.

  59. Andreassen M, Vestergaard H, Kristensen LO. Concentrations of the acute phase reactants high-sensitive C-reactive protein and YKL-40 and of interleukin- 6 before and after treatment in patients with acromegaly and growth hormone deficiency. Clin Endocrinol (Oxf) 2007; 67: 909-916.

  60. Devin JK, Blevins LS, Jr., Verity DK, Chen Q, Bloodworth JR, Jr., Covington J, et al. Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency. J Clin Endocrinol Metab 2007; 92: 3633-3639.

  61. Colao A, Di Somma C, Savastano S, Rota F, Savanelli MC, Aimaretti G, et al. A reappraisal of diagnosing GH deficiency in adults: role of gender, age, waist circumference, and body mass index. J Clin Endocrinol Metab 2009; 94: 4414-4422.

  62. Bates AS, Evans AJ, Jones P, Clayton RN. Assessment of GH status in adults with GH deficiency using serum growth hormone, serum insulin-like growth factor-I and urinary growth hormone excretion. Clin Endocrinol (Oxf) 1995; 42: 425-430.

  63. Clemmons DR. Value of insulin-like growth factor system markers in the assessment of growth hormone status. Endocrinol Metab Clin North Am 2007; 36: 109-129.

  64. Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 2002; 87: 477-485.

  65. Glynn N, Agha A. Diagnosing growth hormone deficiency in adults. Int J Endocrinol 2012; 2012: 972617.

  66. Lissett CA, Jonsson P, Monson JP, Shalet SM. Determinants of IGF-I status in a large cohort of growth hormone-deficient (GHD) subjects: the role of timing of onset of GHD. Clin Endocrinol (Oxf) 2003; 59: 773- 778.

  67. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998; 83: 379-381.

  68. Biller BM, Samuels MH, Zagar A, Cook DM, Arafah BM, Bonert V, et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 2002; 87: 2067-2079.

  69. Finucane FM, Liew A, Thornton E, Rogers B, Tormey W, Agha A. Clinical insights into the safety and utility of the insulin tolerance test (ITT) in the assessment of the hypothalamo-pituitary-adrenal axis. Clin Endocrinol (Oxf) 2008; 69: 603-607.

  70. Corneli G, Di Somma C, Baldelli R, Rovere S, Gasco V, Croce CG, et al. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol 2005; 153: 257- 264.

  71. Bushinsky DA, Gennari FJ. Life-threatening hyperkalemia induced by arginine. Ann Intern Med 1978; 89: 632-634.

  72. Giovacchini G, Nicolas G, Freidank H, Mindt TL, Forrer F. Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy. Eur J Nucl Med Mol Imaging 2011; 38: 1675-1682.

  73. Darzy KH, Aimaretti G, Wieringa G, Gattamaneni HR, Ghigo E, Shalet SM. The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. J Clin Endocrinol Metab 2003; 88: 95-102.

  74. Berg C, Meinel T, Lahner H, Yuece A, Mann K, Petersenn S. Diagnostic utility of the glucagon stimulation test in comparison to the insulin tolerance test in patients following pituitary surgery. Eur J Endocrinol 2010; 162: 477-482.

  75. Conceicao FL, da Costa e Silva A, Leal Costa AJ, Vaisman M. Glucagon stimulation test for the diagnosis of GH deficiency in adults. J Endocrinol Invest 2003; 26: 1065-1070.

  76. Gomez JM, Espadero RM, Escobar-Jimenez F, Hawkins F, Pico A, Herrera-Pombo JL, et al. Growth hormone release after glucagon as a reliable test of growth hormone assessment in adults. Clin Endocrinol (Oxf) 2002; 56: 329-334.

  77. Hoffman AR, Kuntze JE, Baptista J, Baum HB, Baumann GP, Biller BM, et al. Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89: 2048-2056.

  78. Baum HB, Biller BM, Finkelstein JS, Cannistraro KB, Oppenhein DS, Schoenfeld DA, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo- controlled trial. Ann Intern Med 1996; 125: 883- 890.

  79. Biller BM, Sesmilo G, Baum HB, Hayden D, Schoenfeld D, Klibanski A. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency. J Clin Endocrinol Metab 2000; 85: 970-976.

  80. Shalet SM, Shavrikova E, Cromer M, Child CJ, Keller E, Zapletalova J, et al. Effect of growth hormone (GH) treatment on bone in postpubertal GH-deficient patients: a 2-year randomized, controlled, dose-ranging study. J Clin Endocrinol Metab 2003; 88: 4124-4129.

  81. Svensson J, Bengtsson BA, Rosen T, Oden A, Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 2004; 89: 3306-3312.

  82. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, CamBpaulkzaaun oB-,M Cahyaan sGo.n P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. J Clin Endocrinol Metab 2004; 89: 2192-2199.

  83. Rosilio M, Blum WF, Edwards DJ, Shavrikova EP, Valle D, Lamberts SW, et al. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab 2004; 89: 1684-1693.

  84. Hoybye C, Jonsson P, Monson JP, Koltowska-Haggstrom M, Hana V, Geffner M, et al. Impact of the primary aetiology upon the clinical outcome of adults with childhood-onset GH deficiency. Eur J Endocrinol 2007; 157: 589-596.

  85. Kreitschmann-Andermahr I, Poll EM, Reineke A, Gilsbach JM, Brabant G, Buchfelder M, et al. Growth hormone deficient patients after traumatic brain injury--baseline characteristics and benefits after growth hormone replacement--an analysis of the German KIMS database. Growth Horm IGF Res 2008; 18: 472-478.

  86. Baum HB, Katznelson L, Sherman JC, Biller BM, Hayden DL, Schoenfeld DA, et al. Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1998; 83: 3184- 3189.

  87. Murray RD, Skillicorn CJ, Howell SJ, Lissett CA, Rahim A, Smethurst LE, et al. Influences on quality of life in GH deficient adults and their effect on response to treatment. Clin Endocrinol (Oxf) 1999; 51: 565-573.

  88. Hoffman AR, Strasburger CJ, Zagar A, Blum WF, Kehely A, Hartman ML. Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. J Clin Endocrinol Metab 2004; 89: 3224-3233.

  89. Porretti S, Giavoli C, Ronchi C, Lombardi G, Zaccaria M, Valle D, et al. Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T(4) therapy become mandatory? J Clin Endocrinol Metab 2002; 87: 2042-2045.

  90. Giavoli C, Libe R, Corbetta S, Ferrante E, Lania A, Arosio M, et al. Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary- adrenal axis in adult GH-deficient patients. J Clin Endocrinol Metab 2004; 89: 5397-5401.

  91. Svensson J, Fowelin J, Landin K, Bengtsson BA, Johansson JO. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 2002; 87: 2121-2127.

  92. Monson JP, Bengtsson BA, Abs R, Feldt-Rasmussen U, Wuster C. Can growth hormone therapy cause diabetes? KIMS Strategic Committee. Lancet 2000; 355: 1728-1729.

  93. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 2010; 95: 167-177.

  94. Fradkin JE, Mills JL, Schonberger LB, Wysowski DK, Thomson R, Durako SJ, et al. Risk of leukemia after treatment with pituitary growth hormone. JAMA 1993; 270: 2829-2832.

  95. Lopez-Siguero J, Borras Perez MV, Balser S, Khan-Boluki J. Long-term safety and efficacy of the recombinant human growth hormone Omnitrope(R) in the treatment of Spanish growth hormone deficient children: results of a phase III study. Adv Ther 2011; 28: 879-893.

  96. Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002; 360: 273-277.

  97. Ho KK. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 2007; 157: 695-700.




2020     |     www.medigraphic.com